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Introduction
Ultra-orphan drugs are medicines used to treat excep-
tionally rare diseases that are chronically debilitating or
life-threatening. Low patient numbers make it difficult
for pharmaceutical companies to recoup research and
development costs, and consequently these medicines
are generally very expensive on a per patient basis. Eur-
opean Union (EU) regulations promote the development
of orphan drugs; but to contain costs, EU healthcare
systems will increasily need the cost-effectiveness analy-
sis (CEA) of therapies when deciding if they should be
funded. Conventional methods for CEA of drugs for
common conditions do not apply to ultra-orphan drugs;
therefore, additional factors need to be considered.
Objectives
Using the case of ultra-orphan cryopyrin associated peri-
odic syndromes (CAPS) currently investigated by the
EuroFever registry, the RaDiCEA (Rare Diseases & Cost-
Effectiveness Analysis) project is aimed at collecting
prospective efficacy, safety, tolerability, treatment adher-
ence (effectiveness data), cost of illness (COI) informa-
tion, and relative effectiveness of life-long treatment




As a EuroFever registry spin-off, a three-year, interna-
tional, multicentre, observational, cost-effectiveness
study will be conducted in approx. 150 CAPS patients
through the Paediatric Rheumatology INternational
Trials Organisation (PRINTO) network.
Participants
The EuroFever registry project (http://www.printo.it/
eurofever/) involves so far 170 centres of Paediatric
Rheumatology and centres of reference for all autoin-
flammatory diseases in 45 Countries worldwide.
Results
Main outcome measures
They will be the retention on treatment and reasons of
treatment withdrawal for effectiveness. For safety, the
incidence rates of anti-IL-1 agents-emergent adverse
events (AEs) and serious AEs will be evaluated in com-
parison with incidence rates observed in CAPS subjects
not exposed to anti-IL-1 agents. The bases for a cost-
effectiveness model in CAPS will be set by means of a
COI evaluation, and of a comparative economic evalua-
tion of different treatment strategies in the National
Health Systems’(NHS) perspectives, using CEA of direct
health costs (Incremental Cost Effectiveness Ratio -
ICER), and by measuring quality adjusted life years
(QALY), and organ/system damage prevention up to
three years.
Expected results
The RaDiCEA project will assess the long-term effective-
ness of different potentially life-long treatment strategies
and COI, while exploring the feasibility of a new CEA
model to be generated from a rare disease (CAPS) registry.
Conclusion
As expensive medications like “biologicals” show pro-
mising results in some patients with “ultra-orphan” dis-
eases, it becomes more and more important to have
detailed information on as many patients as possible. A
promising new international collaboration aims to
develop a model to evaluate both costs and (long-term)
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benefits in an ultra-orphan group of diseases known as
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